+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of melanoma inhibiting activity levels in malignant melanoma



Prognostic significance of melanoma inhibiting activity levels in malignant melanoma



Melanoma Research 11(6): 627-632



This analytic (phase II) study aimed to investigate the hypothesis that the decline in serum melanoma-inhibiting activity (MIA) levels following initiation of treatment might have prognostic value. The mean serum lactate dehydrogenase (LDH), MIA and S100 levels in patients with malignant melanoma before treatment were higher than in the control group. Patients with visceral dissemination had much higher mean serum MIA levels than patients with nodal spread only. A regression model was constructed to analyse the prognostic factors in patients with advanced stage malignant melanoma. Therapy included surgical excision or lymph node dissection, hypofractionated radiotherapy, and immunotherapy or chemotherapy. Blood samples were collected within 24 h before the initiation of systemic treatment and two or three times more at 20-28 day intervals. Overall survival was investigated by univariate analysis, and correlation with clinical factors was compared using the log-rank test. Gender, primary tumour site, surgery, radiation therapy, serum S100 levels before systemic treatment and choice of chemotherapy were not correlated with the outcome. In addition to the stage of disease, low serum LDH levels before systemic treatment and a decline in serum MIA levels following initiation of systemic treatment predicted a favourable outcome. Metastasis to visceral organs was associated with higher serum MIA levels. Persistence of high serum MIA levels despite systemic treatment predicts an unfavourable prognosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 011206855

Download citation: RISBibTeXText

PMID: 11725209

DOI: 10.1097/00008390-200112000-00009


Related references

Melanoma Inhibiting Activity A new prognostic serum marker in patients with malignant melanoma. Clinical Chemistry & Laboratory Medicine 37(SPEC SUPPL ): S226, June, 1999

Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Modern Pathology 15(5): 532-537, 2002

Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Research 57(15): 3149-3153, 1997

Diagnostic sensitivity of S-100 protein and melanoma-inhibiting activity in the follow-up care of a malignant melanoma. Anticancer Research 19(6D): 5712, 1999

Prognostic significance of lactate dehydrogenase levels in metastatic malignant melanoma. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 192, 1996

Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients. Cytokines, Cellular & Molecular Therapy 7(2): 71-74, 2003

Tyrosinase activity in three types of the malignant melanoma: Superficial spreading melanoma, mentigo maligna melanoma and Nodular Melanoma. Archives of Dermatological Research 252(3): 193-201, 1975

Tyrosinase activity in three types of the malignant melanoma: superficial spreading melanoma, lentigo maligna melanoma and nodular melanoma. Archiv für Dermatologische Forschung 252(3): 193-201, 1975

Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. Journal of Skin Cancer 2014: 843214-843214, 2014

Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: Low levels of MIA mRNA are present in various cell types and in peripheral blood. British Journal of Cancer 81(6): 1066-1070, 1999

Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7): 1737-1745, 2003

The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Medical Oncology 22(3): 241-246, 2005

Prognostic value of clinical and pathological parameters of stage i malignant melanoma on a multivariable analysis the experience of the french group of research on malignant melanoma on 475 cases followed from 15 to 113 months. Proceedings of the American Association for Cancer Research Annual Meeting 27: 186, 1986

Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 47(5): 955-962, 1981

Electron microscopic observations of malignant melanoma. The comparative studies on intracellular organelle in the malignant melanoma of the choroid and in the malignant melanoma of the skin. Nippon Ganka Gakkai Zasshi 79(6): 567-582, 1975